SolasCure selected for Innovate UK Global Incubator program in Houston

• Program delivered in partnership with the Texas Medical Center

• The program will support Aurase Wound Gel for future entry into the U.S. market, advancing SolasCure’s mission to transform chronic wound care for millions of patients worldwide.

CAMBRIDGE, England, June 3, 2024–(BUSINESS WIRE)–SOLASCURE Ltd (SolasCure), a biotechnology company developing a new treatment to transform chronic wound care, today announced that it has been selected for Innovate UK’s Global Incubator Program at Houston, United States. The program, focused on commercializing innovative solutions to address unmet healthcare needs, is delivered in partnership with the Texas Medical Center (TMC), the largest medical complex in the world. The program will support the future U.S. market entry of Aurase Wound Gel, SolasCure’s first investigational product intended to treat millions of patients suffering from chronic wounds worldwide.

SolasCure is one of 16 healthcare companies selected for Houston’s Global Incubator program. The company’s participation in the program builds on recent European Innovation Council Accelerator Grants and Innovate UK Biomedical Catalyst Grants to further advance the development of Aurase Wound Gel.

The 6-month Global Incubator program is fully funded by Innovate UK and includes two intensive market visits to Houston, a dynamic health research hub with more than 1,760 life sciences companies, healthcare facilities and research institutes. These visits will focus on customer discovery, mentoring and investor networking, including engagement with hospital administrators, procurement and reimbursement professionals, to support Aurase’s future entry Wound Gel on the American market.

“It is a real boost to our journey at SolasCure to be selected for this global incubator program, continuing the momentum of our recent EIC accelerator and BMC grants secured. This represents another key element of TMC/TMC-Innovation’s industry validation and recognition. , global leaders in medical innovation, that SolasCure has the potential to address a huge unmet need,” commented Lee Harle, CEO of SolasCure. “TMC is the largest medical complex in the world and access to this expertise and network will be invaluable in strengthening our plans for SolasCure and Aurase Wound Gel in the United States. »

For more information about SolasCure, please visit: https://solascure.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603567614/en/

Contacts

Sarah Jeffery
Zyme Communications
Tel: +44 (0) 7771 730919
Email: [email protected]